Breast cancer drug trastuzumab induces cardiac toxicity: evaluation of human epidermal growth factor receptor 2 as a potential diagnostic and prognostic marker

Canadian Journal of Physiology and Pharmacology
Taylor A Johnson, Dinender K Singla

Abstract

Breast cancer is one of the most prevalent forms of cancer in the United States and worldwide. Cancer occurs through the uncontrolled development of new abnormal cell growth. Clinicians and researchers strive to improve diagnostics and treatments in pursuit of remedying breast cancer, while limiting or removing any potential side effects that may arise. Unfortunately, traditional treatments, such as anthracyclines (i.e., doxorubicin), can damage the cardiovascular system. Recent strategies have utilized antibody-based compounds as singular treatments, or in conjunction with other treatments, with the aim to minimize side effects. The human epidermal growth factor receptor 2 (HER2) protein has been the target of numerous antibody-based breast cancer therapies, such as trastuzumab (TZM) and trastuzumab emtansine (T-DM1). This review will discuss the HER2 receptor as a diagnostic marker in targeting breast cancer using the therapeutic agents TZM and T-DM1, as well as discuss the induced cardiac toxicity following TZM and T-DM1 treatments.

References

Sep 24, 1998·The New England Journal of Medicine·P K Singal, N Iliskovic
Feb 17, 2000·The Journal of Clinical Investigation·C S SeitzP A Khavari
Mar 31, 2000·Nature Medicine·R A ClynesJ V Ravetch
Mar 22, 2002·Nature·Yotaro IzumiRakesh K Jain
May 2, 2002·Nature Medicine·Steven A CroneKuo-Fee Lee
Jun 6, 2002·Journal of the National Cancer Institute·Soonmyung PaikNorman Wolmark
Jun 20, 2002·Proceedings of the National Academy of Sciences of the United States of America·Cemil OzcelikAlistair N Garratt
Sep 26, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian Leyland-JonesParviz Ghahramani
Jan 8, 2004·Chemical & Pharmaceutical Bulletin·John M CassadyEckhard Leistner
Feb 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Syed K MohsinJenny C Chang
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Nov 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark N Levine
Feb 24, 2006·The New England Journal of Medicine·Kenneth R Chien
Mar 1, 2006·Expert Opinion on Biological Therapy·Hongsheng Xie, Walter A Blättler
Jan 19, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G ValabregaM Aglietta
Aug 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christoph A RitterCarlos L Arteaga
Aug 21, 2007·Accounts of Chemical Research·Ravi V J Chari
Sep 17, 2008·Oncogene·T L Yuan, L C Cantley
Nov 18, 2008·Cancer Research·Gail D Lewis PhillipsMark X Sliwkowski
Dec 17, 2008·Breast Cancer Research and Treatment·Deepa WadhwaDavinder S Jassal
Mar 23, 2010·Nature Reviews. Drug Discovery·Trevor T HanselAndrew J T George
Jul 22, 2010·Endocrine-related Cancer·Marion T Weigel, Mitch Dowsett
Aug 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniela CardinaleCarlo M Cipolla
May 10, 2011·Cancer Treatment Reviews·Chantal TséPierre-Jean Lamy
Jul 7, 2011·Clinical Breast Cancer·Howard A BurrisGail D Lewis Phillips
Aug 11, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C SerranoS Di Cosimo
Feb 22, 2012·Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology·Ronny S JijiMichael Salerno
Apr 24, 2012·The Breast : Official Journal of the European Society of Mastology·J BonastreS Koscielny
Jul 13, 2013·Journal of Internal Medicine·A J Redig, S S McAllister
Jul 16, 2013·Targeted Oncology·Véronique Diéras, Thomas Bachelot
Oct 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffUNKNOWN College of American Pathologists

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.